WMA Declaration of Helsinki – Ethical Principles f... ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Ask the Heart Doctor | Heart Valve Disease and Sur...
Drug candidate slows motor neuron disease progress...
A Professional Overview of Hypertension ...
Long-term physical activity protects against metabolic syndr...
January 17,2026
Controlling hypertension can reduce dementia risk—even when ...
January 16,2026
Assessing methods for improving access to trauma care for ki...
January 15,2026
Portable device could help scientists track Alzheimer's dise...
January 14,2026
Neurons use physical signals, not electricity, to stabilize ...
January 13,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?

Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?

Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?Uses, Procedure, and ResultsByLynne Eldridge, MDUpdated on June 13, 2023Medically reviewed byDoru Paul,
Oncology March 17,2024
Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?

Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?

Red Cell Distribution Width (RDW) Blood Test Is High: What Does It Mean?Uses, Procedure, and ResultsByLynne Eldridge, MDUpdated on June 13, 2023Medically reviewed byDoru Paul,
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Dr. Fauci among hundreds who've contract...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
Announcement of the 2025 Nobel Prize in ...
More News
Why a promising breast cancer drug doesn't work—and how to improve it

Why a promising breast cancer drug doesn't work—and how to improve it

by Katherine Fenz,Rockefeller UniversityER-mediated transcriptional resistance to BD inhibition. Credit:Nature Structural & Molecular Biology(2024). DOI: 10.1038/s41594-024-01384
Oncology September 28,2024
Why a promising breast cancer drug doesn't work—and how to improve it

Why a promising breast cancer drug doesn't work—and how to improve it

by Katherine Fenz,Rockefeller UniversityER-mediated transcriptional resistance to BD inhibition. Credit:Nature Structural & Molecular Biology(2024). DOI: 10.1038/s41594-024-01384
Oncology September 28,2024
New mammogram rule gives women more details to guard against breast cancer

New mammogram rule gives women more details to guard against breast cancer

by Helena Oliviero, The Atlanta Journal-ConstitutionCredit: Unsplash/CC0 Public DomainA new federal rule takes effect Tuesday that could potentially help more women spot breast cancer earlier. The FDA
Oncology September 28,2024
New mammogram rule gives women more details to guard against breast cancer

New mammogram rule gives women more details to guard against breast cancer

by Helena Oliviero, The Atlanta Journal-ConstitutionCredit: Unsplash/CC0 Public DomainA new federal rule takes effect Tuesday that could potentially help more women spot breast cancer earlier. The FDA
Oncology September 28,2024
Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal

Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal

by ECOG-ACRIN Cancer Research GroupCredit: CC0 Public DomainResults from a clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) show a striking improvement for patients who received che
Oncology September 28,2024
Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal

Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal

by ECOG-ACRIN Cancer Research GroupCredit: CC0 Public DomainResults from a clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) show a striking improvement for patients who received che
Oncology September 28,2024
Common diabetes drug slows growth of normal cells carrying cancer mutation, finds study

Common diabetes drug slows growth of normal cells carrying cancer mutation, finds study

byWellcome Trust Sanger InstitutePIK3CA mutant clones in human esophageal epithelium. Credit:Nature Genetics(2024). DOI: 10.1038/s41588-024-01891-8A common diabetes medication, metfo
Oncology September 28,2024
Common diabetes drug slows growth of normal cells carrying cancer mutation, finds study

Common diabetes drug slows growth of normal cells carrying cancer mutation, finds study

byWellcome Trust Sanger InstitutePIK3CA mutant clones in human esophageal epithelium. Credit:Nature Genetics(2024). DOI: 10.1038/s41588-024-01891-8A common diabetes medication, metfo
Oncology September 28,2024
Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an accepta
Oncology September 27,2024
Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an accepta
Oncology September 27,2024
Sex matters in how, when, and where melanomas develop

Sex matters in how, when, and where melanomas develop

byElsevierFitted temporal trend of invasive cutaneous melanoma incidence (1982- 2018) for males vs. females from three populations (Queensland, US Whites, Scotland), by body site. Credit:J
Dermatology September 27,2024
Sex matters in how, when, and where melanomas develop

Sex matters in how, when, and where melanomas develop

byElsevierFitted temporal trend of invasive cutaneous melanoma incidence (1982- 2018) for males vs. females from three populations (Queensland, US Whites, Scotland), by body site. Credit:J
Dermatology September 27,2024
New multimodal signature could predict immunotherapy success

New multimodal signature could predict immunotherapy success

byUniversity of InnsbruckCredit:iScience(2024). DOI: 10.1016/j.isci.2024.110529An international team of researchers led by Francesca Finotello from the Digital Science Center (DiSC)
Oncology September 27,2024
New multimodal signature could predict immunotherapy success

New multimodal signature could predict immunotherapy success

byUniversity of InnsbruckCredit:iScience(2024). DOI: 10.1016/j.isci.2024.110529An international team of researchers led by Francesca Finotello from the Digital Science Center (DiSC)
Oncology September 27,2024
Double trouble for triple-negative breast cancer: Two-pronged strategy restores immunotherapy sensitivity

Double trouble for triple-negative breast cancer: Two-pronged strategy restores immunotherapy sensitivity

by Kimberly McGhee,Medical University of South CarolinaTumor-fighting immune cells in the tumor before (left) and after (right) combination therapy. After combination therapy, many more tumor-fi
Oncology September 27,2024
Double trouble for triple-negative breast cancer: Two-pronged strategy restores immunotherapy sensitivity

Double trouble for triple-negative breast cancer: Two-pronged strategy restores immunotherapy sensitivity

by Kimberly McGhee,Medical University of South CarolinaTumor-fighting immune cells in the tumor before (left) and after (right) combination therapy. After combination therapy, many more tumor-fi
Oncology September 27,2024
Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutations

Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutations

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung can
Oncology September 27,2024
Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutations

Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutations

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung can
Oncology September 27,2024
Aumolertinib shows improved progression-free survival in stage III non-small cell lung cancer

Aumolertinib shows improved progression-free survival in stage III non-small cell lung cancer

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-
Oncology September 27,2024
Aumolertinib shows improved progression-free survival in stage III non-small cell lung cancer

Aumolertinib shows improved progression-free survival in stage III non-small cell lung cancer

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-
Oncology September 27,2024
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... Health spending has been rising across rich countries with different systems ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com